NCT06581497Completed
ICIs With and Without MWA in Advanced Hepatocellular Carcinoma
Comparing the Efficacy of ICIs With and Without MWA in Advanced Hepatocellular Carcinoma in Real-World Clinical Practice
Source: ClinicalTrials.gov · Last updated 14 Jan 2026
Brief summary (registry, in English)
Immunotherapy has become the main treatment recommendation for HCC. MWA treatment induces peripheral immune response, which may enhance the effectiveness of immunotherapy for advanced HCC. This study aims to compare the efficacy and safety of ICIs combined with MWA compared to ICIs alone. The study will compare two groups: ICIs and ICIs+MWA. Main objectives: OS, PFS Secondary objectives: CR PR、SD、PD、ORR、DCR、AEs This study addresses the efficacy and safety of using ICIs in combination with MWA compared to ICIs alone for advanced HCC patients. The investigators' study aims to evaluate the necessity of immunotherapy combined with targeted drugs or microwave ablation in patients with advanced hepatocellular carcinoma in the real world, providing relevant clinical data for the treatment selection of HCC patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 52 (actual)
- First submitted
- 30 Aug 2024
- Start date
- 1 Jan 2022
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- The First People's Hospital of Neijiang
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06581497
What you commit to
- Study type: Observational
- Participants enrolled: 52
- From 1 Jan 2022 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Other treatments were received during the process of receiving immunotherapy or immunotherapy combined with MWA treatment.
Other illness
- There is a portal vein cancer thrombus present.
- There is active bleeding present.
- There are interstitial lung diseases, pulmonary fibrosis, and autoimmune diseases present.
Other
- It has been determined that the inclusion criteria cannot be met.
- Enhanced CT or MRI shows more than 3 active lesions in the liver, and the shortest diameter of a single lesion is greater than 3cm.
- The extrahepatic metastatic lesions have not been well controlled.
Who the study is looking for
- Gender is not limited, age range is 19-80 years old.
- Meets the clinical diagnostic criteria for HCC.
- Progress after first-line treatment.
- CNLC staging: Stage IIa, IIb, or IIIb of advanced HCC.
- Child Pugh liver function grading score 5-7 points.
- The ECOG (Eastern Cooperative Oncology Group) score ranges from 0 to 1.
- The patient has a certain degree of compliance with the treatment plan and follow-up performance.
- For patients infected with hepatitis B, antiviral treatment with anti hepatitis B virus drugs should be carried out before receiving treatment; And the hepatitis B DNA titer of the patient was less than 10\^2 IU/ml.
Age in the registry: 19 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Second People's Hospital of Neijiang City Coordinator of this site? Confirm its status | Neijiang | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.